Reports suggest AstraZeneca has engaged in discussions with its US counterpart, Bristol Myers Squibb, regarding a potential merger that could establish a pharmaceutical behemoth valued at over £300 billion.
The Financial Times indicated that these talks between the two drugmakers have been ongoing in recent months.